Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light

por Wessels, Mark HJ, Van Lierop, Zoë YGJ, Noteboom, Samantha, Strijbis, Eva MM, Heijst, Johannes A, Van Kempen, Zoé LE, Moraal, Bastiaan, Barkhof, Frederik, Uitdehaag, Bernard MJ, Schoonheim, Menno M, Killestein, Joep, Teunissen, Charlotte E
Publicado 2023

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis

por van Lierop, Zoë YGJ, Wieske, Luuk, Koel-Simmelink, Marleen JA, Chatterjee, Madhurima, Dekker, Iris, Leurs, Cyra E, Willemse, Eline AJ, Moraal, Bastiaan, Barkhof, Frederik, Eftimov, Filip, Uitdehaag, Bernhard MJ, Killestein, Joep, Teunissen, Charlotte E
Publicado 2021

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis

por van Lierop, Zoë YGJ, Noteboom, Samantha, Steenwijk, Martijn D, van Dam, Maureen, Toorop, Alyssa A, van Kempen, Zoé LE, Moraal, Bastiaan, Barkhof, Frederik, Uitdehaag, Bernard MJ, Schoonheim, Menno M, Teunissen, Charlotte E, Killestein, Joep
Publicado 2022

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic

por van Lierop, Zoë YGJ, Toorop, Alyssa A, van Ballegoij, Wouter JC, Olde Dubbelink, Tom BG, Strijbis, Eva MM, de Jong, Brigit A, van Oosten, Bob W, Moraal, Bastiaan, Teunissen, Charlotte E, Uitdehaag, Bernard MJ, Killestein, Joep, van Kempen, Zoé LE
Publicado 2021